CEM/C1（人急性淋巴細(xì)胞白血病細(xì)胞）
CBP60711
詢 價(jià)
索取STR
產(chǎn)品描述
產(chǎn)品數(shù)據(jù)庫(kù)
| I. General information | |
| Synonyms: | CEM/C1 |
| Background: | CEM/C1 is a camptothecin (CPT) resistant derivative of the human T cell leukemia cell line CCRF-CEM (see ATCC CCL-119). The cell line was selected and subcloned in 1991 for resistance to CPT. |
| Species: | Homo sapiens, human |
| Tissue: | peripheral blood |
| Disease: | acute lymphoblastic leukemia |
| Gender: | Caucasian,Female,4 years |
| Morphology: | lymphoblast |
| Growth Mode: | suspension |
| Doubling Time: | 26 hrs |
| DNA Profile: | Our Cell Line Authentication Service |
| Culture Medium: |
RPMI-1640 +10%FBS CEM/C1完全培養(yǎng)基，# CBP60711M |
| Cryopreservation medium: | 90%FBS+10%DMSO |
| Tumor Formation: | Yes, in nude mice,(The cells form serially transplantable intercranial and subcutaneous tumors.) |
| Comments: | This cell line exhibits cross resistance to both the water soluble (topotecan) and water insoluble (9-amino-CPT and 10,11-methylenedioxy-CPT) analogs of CPT. CEM/C1 cells are approximately 31 fold less sensitive to CPT than the parental CEM cells. CEM/C1 cells display atypical multidrug resistance (MDR) and altered topoisomerase I catalytic activity. Resistance to CPT is stable for up to six months. For more information, please contact us (4008-750-250). |
